Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity

NCT03265574 is registered in ClinicalTrials.gov with South Tees Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT03265574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03265574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity
Lead sponsor
South Tees Hospitals NHS Foundation Trust
Phase
Phase 3
Overall status
Completed
Start date
October 4, 2017
Completion date
August 4, 2023
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non hodgkin lymphoma